CliffBio
small molecule

KEPPRA

LEVETIRACETAM

Loss of exclusivity—loss of exclusivity
CompanyUCB →See this company's full patent-cliff portfolio

Drug detail

Brand nameKEPPRA
Active ingredientLEVETIRACETAM
Strength500MG/5ML (100MG/ML)
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJuly 2006
Marketing statusRX

More from UCB

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

KEPPRA patent cliff — loss of exclusivity — | CliffBio